Aurinia Pharmaceuticals Inc.'s shares closed up 10.86% on Monday with a little over 9 million shares traded. There was no remarkable news to explain the move but last week the company announced that it had resolved a temporary noncompliance with NASDAQ's Audit Committee. The clinical stage biopharmaceutical company has a lead product called voclosporin which is designed to be used with CellCept to treat lupus nephritis (LN) patients. It has been granted "fast track status" by the U.S. Food & Drug Administration (FDA). According to the Lupus Research Alliance, lupus nephritis is a debilitating, autoimmune disease that causes inflammation of a patient's kidney.